Skip to main content

Advertisement

Table 1 Patients’ baseline characteristic

From: Centrosome associated genes pattern for risk sub-stratification in multiple myeloma

  Training cohorta Validation cohorta
No. of patients 73 78
Follow-up median (min–max) [month] 23.6 (0.3–97.0) 18.6 (0.1–250.0)
Gender: males–females 49.3–50.7 % 55.1–44.9 %
Age median (range) [years] 69 (38–84) 66 (40–90)
ISS stage: I–II–III 28.8 %–27.3 %–43.9 % 24.7 %–35.1 %– 40.3 %
Durie-Salmon stage: I–II–III 4.3 %–14.3 %–81.4 % 3.8 %–29.5 %–66.7 %
Durie-Salmon substage: A–B 81.4 %–18.6 % 75.6 %–24.4 %
Ig isotype: IgG–IgA–FLC-Non-secr. 60.3 %–23.5 %–16.2 % 57.7 %–28.2 %–1.3 %–12.8 %
Light chains: kapp–lambda 58.0 %–42.0 % 53.8 %–46.2 %
Plasma cell infiltration in bone marrow 34.4 % (0.8 %–93.6 %) 36.0 % (2.2 %–81.2 %)
No. of previous treatment lines
 None (first line treatment) 57.7 % (41/71) 64.1 % (50/78)
 One 19.7 % (14/71) 15.4 % (12/78)
 Two 8.5 % (6/71) 10.3 % (8/78)
 More (>2) 14.1 % (10/71) 10.3 % (8/78)
Treatment regimen
 Bortezomib-based 47.8 % (32/67) 64.9 % (50/77)
 Thalidomide-based 14.9 % (10/67) 10.4 % (8/77)
 Lenalidomide-based 25.4 % (17/67) 18.2 % (14/77)
 Others 11.9 % (8/67) 6.5 % (5/77)
Treatment response
 CR-VGPR-PR-MR-SD-PG 12.3 %–29.8 %–22.8 %–5.3 %–5.3 %–26.3 % 10.8 %–20.0 %–27.7 %–7.7 %–4.6 %–29.2 %
Biochemical parameters
 Hemoglobin (g/l) 105.5 (67.0–151.0) 95.5 (65.9–146.0)
 Thrombocytes (×109) 192.0 (33.0–416.0) 188.5 (55.0–485.0)
 Calcium (mmol/l) 2.29 (1.74–23.37) 2.32 (1.75–2.78)
 Albumin (g/l) 38.2 (21.1–54.1) 35.7 (17.4–52.2)
 Creatinine (umol/l) 98.5 (53.0–783.0) 94.5 (30.0–849.0)
 β2-microglobulin (mg/l) 4.70 (1.79–42.60) 4.61 (1.62–50.0)
 Lactate dehydrogenase (ukat/l) 3.72 (1.53–22.92) 3.36 (1.14–7.77)
 C-reactive protein (mg/l) 3.6 (0.0–174.3) 4.0 (0.0–149.3)
 Monoclonal Ig (g/l) 29.8 (0.0–92.6) 30.2 (0.0–85.6)
Chromosomal abnormality
 Deletion 13q14 49.2 % (30/61) 60.0 % (39/65)
 Deletion 17p13 8.3 % (5/60) 13.8 % (9/65)
 Translocation t(4;14) 46.9 % (15/32) 44.4 % (16/36)
 Amplification 1q21 56.9 % (37/65) 54.5 % (36/66)
 Hyperdiploidy (H-MM) 45.5 % (30/66) 47.0 (17/46)
  1. CR complete response; VGPR very good partial response; PR partial response; MR minimal response; SD stable disease; PG progression
  2. aBoth cohorts have no significant difference in basic clinical parameters